Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03UZP
|
|||
| Former ID |
DIB000661
|
|||
| Drug Name |
RG7888
|
|||
| Synonyms |
MOXR0916
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Urothelial carcinoma [ICD-11: 2C92.0] | Phase 2 | [1] | ||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TAX transcriptionally-activated glycoprotein 1 (OX40) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| TSLP Signaling Pathway | ||||
| Reactome | TNFs bind their physiological receptors | |||
| WikiPathways | Vitamin D Receptor Pathway | |||
| TSLP Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.